Rheumatoid Arthritis
From the Journals
DMARDs taper-to-discontinuation trial deemed inconclusive
For patients with RA in sustained remission taking half doses of conventional synthetic DMARDs, the risk of flare was similar to that from...
News from the FDA/CDC
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
From the Journals
Tofacitinib may have possible protective effect against ILD in RA
“Most of the biologic therapies had similar rates of developing ILD, but the JAK inhibitor tofacitinib had a reduced risk,” said study first...
Conference Coverage
New JAK inhibitor study data confirm benefit in alopecia areata
Deuruxolitinib (CTP-543), an inhibitor of the JAK1 and JAK2 enzymes, has the potential to become the second JAK inhibitor available for the...
Latest News
JAK inhibitor safety warnings drawn from rheumatologic data may be misleading in dermatology
The recently approved deucravacitinib is the only JAK inhibitor that has so far been exempt from these warnings.
From the Journals
Call it preclinical or subclinical, ILD in RA needs to be tracked
Despite ILD being a leading cause of death in RA patients, there are no clinical guidelines for monitoring this lung condition in this population...
News from the FDA/CDC
FDA approves first biologic treatment for polymyalgia rheumatica
The interleukin-6 receptor antagonist sarilumab (Kevzara) will be indicated in adults who have had an inadequate response to corticosteroids or...
From the Journals
Bacteremia, antibodies link periodontal disease to RA development and activity
Researchers found frequent and repeated episodes of oral bacteria in the blood of patients with periodontal disease and rheumatoid arthritis, in a...
Feature
What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
Physicians surveyed from four different specialties reported that they were generally comfortable prescribing biosimilars, but greater discounts...
Conference Coverage
Expert offers caveats to perioperative antirheumatic drug guideline
Experts say the 2022 ACR/AAHKS guideline on perioperative management of antirheumatic medications in total hip and total knee arthroplasty have a...
Latest News
New influx of Humira biosimilars may not drive immediate change
As many as 8-10 adalimumab biosimilars are anticipated to come on the market this year, giving mainstay drug Humira some vigorous competition.